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Abstract
Introduction: Several studies have reported that TNFa is substantially increased within skin lesions of patients with
discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and dermatomyositis (DM)
compared to controls. Elevated TNFa has been reported in the sera of some patients with systemic lupus
erythematosus, DLE and SCLE, but not in the sera of patients with DM. Because of the key pathogenic role of
autoimmunity in these diseases, in this study we sought to evaluate TNFa production by a readily available source
of immune cells (namely, peripheral blood mononuclear cells (PBMCs)) taken from controls and from patients with
cutaneous lupus or DM.
Methods: Freshly isolated PBMCs were cultured overnight, and TNFa protein accumulation in conditioned
medium was determined. In addition, flow cytometry using cell-type-specific markers was performed to determine
the sources of TNFa. One-way analysis of variance and Dunnett’s multiple comparisons test were performed for
statistical comparisons.
Results: Accumulation of TNFa protein in conditioned medium containing PBMCs from DLE patients, but not from
SCLE, TLE or DM patients, was significantly greater (19-fold) than that from controls (P < 0.001). In DLE PBMCs,
increased TNFa was produced by circulating monocytes and myeloid dendritic cells (mDCs). The mean TNFa
fluorescence intensity, but not the total number, of both monocytes and mDCs (P < 0.01) from DLE patients was
significantly greater (2.3-fold) than that of controls. There were significantly more (13.3-fold) mDCs with intracellular
TNFa in blood from DLE patients (P < 0.001) and DM patients (P < 0.001) compared to controls. Most importantly,
a positive correlation was seen in DLE patients between their disease activity measured using the Cutaneous Lupus
Erythematosus Disease Area and Severity Index and TNFa protein secretion (r = 0.61, P < 0.08).
Conclusions: TNFa protein production by PBMCs is greater in DLE patients than in patients with other cutaneous
forms of lupus and DM or in controls. Flow cytometric studies demonstrated that circulating monocytes and mDCs
contributed to this increased TNFa production. Monocytes and mDCs are present in lesional skin, and the
increased TNFa production by these cells and other PBMCs likely increase the number of inflammatory cells seen
in DLE skin relative to other subsets of cutaneous lupus erythematosus and DM. These results provide a possible
biological explanation for the denser infiltrate seen in DLE relative to DM.
Introduction
Lupus erythematosus (LE) is a chronic autoimmune
inflammatory disease. Skin involvement occurs in 70%
to 85% of all patients with LE [1]. Cutaneous disease is
classified as LE-specific or LE-nonspecific, based on
assessments of the morphology of the cutaneous lesions
and the results of histopathologic examinations [2]. LE-
specific skin lesions are divided into three broad cate-
gories that include chronic cutaneous lupus erythemato-
sus (CCLE), subacute cutaneous lupus erythematosus
(SCLE) and acute cutaneous lupus erythematosus [3].
Herein we focus on two subsets of CCLE: (1) discoid
lupus erythematosus (DLE) and tumid lupus erythema-
tosus (TLE) and (2) SCLE. DLE typically presents as
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scaly, erythematous, disk-shaped patches and plaques,
whereas TLE manifests as single or multiple raised poly-
cyclic erythematous plaques with a bright reddish or
violaceous smooth surface that does not scar [1]. SCLE
typically presents as erythematous papulosquamous,
psoriasiform plaques or annular-polycyclic plaques and
the lesions typically resolve without scarring [4]. Derma-
tomyositis (DM) is a chronic inflammatory disorder of
the skin and muscles, with histologic findings similar to
SCLE [5,6].
TNFa is a critical proinflammatory cytokine that is
implicated in the pathogenesis of multiple inflammatory
diseases. TNFa can be produced by many different cell
types including monocytes, macrophages, dendritic cells,
T and B lymphocytes, natural killer cells, neutrophils,
mast cells, endothelial cells, fibroblasts and keratinocytes
[7-9]. TNFa is produced as pro-TNFa, which is
expressed on the plasma membrane, where it can be
cleaved in the extracellular domain by ADAM17 (also
known as “TACE,” or TNFa-converting enzyme), which
is a matrix metalloproteinase, and results in the release
of TNFa in a soluble form [10]. ADAM17 mRNA
expression was found to be increased in lesional skin
from psoriasis patients [11]. Both membrane-associated
and soluble TNFa are active [5].
Several studies have examined TNFa in skin lesions
and serum of patients with CLE and DM. TNFa is
increased in lesional skin of patients with DLE and
SCLE compared to controls [12-15]. DM lesional skin
expresses TNFa, but staining has been found to be
more evident in DLE patients and absent in control spe-
cimens [5]. TNFa was increased in muscle biopsies of
DM patients [16]. TNFa has been reported to be ele-
vated in sera of some patients with systemic lupus
erythematosus (SLE), DLE and SCLE, but not in that of
patients with DM [17-20]. In vitro production of TNFa
by unstimulated PBMCs from juvenile DM patients was
measured in a previous study in which the investigators
found that PBMCs from children who had a disease
course ≥ 36 months produced more TNFa compared to
PBMCs from juvenile DM patients who had had the dis-
ease < 36 months [21]. As there are data regarding
TNFa expression in the skin and sera of CLE and DM
patients, but, to the best of our knowledge, minimal
data regarding TNFa production from the PBMCs of
these patients, the aim of our study was to evaluate the




Twenty-one DLE, ten SCLE, ten TLE and eighteen DM
patients were recruited from the outpatient autoimmu-
nity clinic in the Department of Dermatology at the
Hospital of the University of Pennsylvania. All subjects
who had the diagnosis of DLE, SCLE, TLE and/or DM
were invited to participate in the study. Seven of the
DLE patients and one of the SCLE patients had SLE as
well. All of the recruited patients were receiving therapy
to treat their disease (see Table 1). Eighteen people
without LE, DM or any autoimmune disease were
recruited as controls. To be eligible for the study, con-
trols must not have been on corticosteroids or immuno-
suppressive drugs.
Demographic information and data regarding current
medications and comorbid illnesses were collected from
all subjects. The treating dermatologist evaluated each
LE and DM patient by performing a complete physical
examination and assessing the patient based on Cuta-
neous Lupus Erythematosus Disease Area and Severity
Index (CLASI) and Systemic Lupus Erythematosus Dis-
ease Activity Index (SLEDAI) scores for LE patients and
the Cutaneous Dermatomyositis Area and Severity
Index (CDASI) scores for DM patients to measure dis-
ease activity and damage [22,23]. This study was
approved by the Institutional Review Board (IRB) at our
institution, and all PBMCs were obtained according to
the IRB protocol. The Declaration of Helsinki protocols
were followed, and patients gave their written, informed
consent.
Cell culture and TNFa determination by ELISA
PBMCs were separated from heparinized venous blood
of patients with DLE, SCLE, TLE and DM, as well as
from controls, on an endotoxin-free Ficoll-Paque
PLUS™ gradient (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). PBMCs were cultured overnight in
RPMI 1640 medium supplemented with 10% fetal
bovine serum, 1% L-glutamine and 1% penicillin-strep-
tomycin at 37°C and 5% CO2. The following morning
PBMCs (1 × 105 cells in 0.2 ml per well) were plated in
96-well plates (Falcon, Franklin Lakes, NJ, USA) and
cultured for 24 hours at 37°C and 5% CO2. Conditioned
media were then collected and stored at -80°C. TNFa
was quantitated by ELISA according to the manufac-
turer’s protocol (BD Biosciences, San Diego, CA, USA).
All determinations were performed in triplicate. The
viability of cells was measured by trypan blue staining.
Flow cytometric analysis
Prior to intracellular staining for TNFa, PBMCs were
cultured in medium for 4 hours in the presence of bre-
feldin A (1 μg/ml; Invitrogen/Life Technologies, Carls-
bad, CA, USA). To detect intracellular expression of
TNFa in dendritic cells, approximately 106 PBMCs per
sample were stained with lineage 1 cocktail-fluorescein
isothiocyanate (FITC) (lineage cocktail containing anti-
bodies against CD3, CD14, CD16, CD19, CD20 and
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CD56), anti-human leukocyte antigen (HLA)-DR-perdi-
nin-chlorophyll-protein (PerCp) and anti-CD123-phy-
coerythrin (PE) (plasmacytoid dendritic cells (pDCs)) or
anti-CD11c-PE (myeloid dendritic cells (mDCs)) for 30
minutes on ice, followed by 15-minute incubation with
fixation reagent A (FIX & PERM; Invitrogen/Life Tech-
nologies). Cells were then washed, permeabilized with
reagent B (FIX & PERM; Invitrogen Life/Technologies)
and stained with anti-TNFa-allophycocyanin (anti-
TNFa-APC) antibody (or an appropriate isotype con-
trol) for 15 minutes at room temperature.
To detect intracellular expression of TNFa in mono-
cytes, PBMCs were stained with anti-CD64-FITC and
anti-CD14-PE followed by anti-TNFa-APC or an appro-
priate isotype control as described above. To detect
intracellular expression of TNFa in T cells, PBMCs
were stained with anti-CD3-FITC followed by anti-
TNFa-APC or an appropriate isotype control as
described above. All antibodies used were purchased
from BD Biosciences.
Cells were analyzed using a FACSCalibur flow cyt-
ometer (BD Biosciences, San Jose, CA, USA) with BD
CellQuest software (BD Biosciences) at the Flow Cyto-
metry and Cell Sorting Core, Abramson Cancer Center,
University of Pennsylvania, Philadelphia, PA, USA. We
acquired 150,000 events of live cells.
Statistical analysis
One-way analysis of variance followed by Dunnett’s
multiple comparisons test was used for statistical evalua-
tion as appropriate. P values less than 0.05 in the post
hoc test were considered significant. Correlations were
calculated by performing a Pearson correlation test.
Results
Study population
The demographic and clinical characteristics of the
study population are summarized in Table 1. Seven of
the DLE patients and one of the SCLE patients had SLE,
which did not affect the study results, because removal
of these patients from their respective groups had no
effect on mean values or statistical significance. All of
the recruited patients were receiving therapy to treat
their disease; however, there was no correlation between
the therapy that the patients were receiving and the
results obtained.
TNFa release from unstimulated DLE PBMCs was
significantly elevated and correlated with disease activity
Initially, we compared the amount of TNFa released
from PBMCs of nine DLE, five SCLE, five TLE and
eight DM patients, as well as eight controls, by ELISA.
Compared to controls, DLE PBMCs produced signifi-
cantly greater amounts of TNFa (P < 0.001) (Figure 1).
However, SCLE, TLE and DM PBMCs did not produce
significantly greater amounts of TNFa compared to
controls. The variation of the triplicate of TNFa levels
for each patient was < 10%. The production of TNFa
was not induced by lipopolysaccharide (LPS) contamina-
tion, because the maximal level of LPS detected by
Limulus amoebocyte assay (Associates of Cape Cod,
East Falmouth, MA, USA) was < 0.015 EU/ml (< 1.5 pg/
Table 1 Patient demographics and clinical characteristicsa
Disease Sex (n) Race (n) Mean age, years
(range)
Mean CLASI or CDASI score Medications (patients, n)























42.9 (25 to 57) 10.1 Antimalarials, 10
Methotrexate, 1














31.2 (26 to 57) N/A N/A
aAA = African American; CDASI = Cutaneous Dermatomyositis Area and Severity Index; CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index;
DLE = discoid lupus erythematosus; DM = dermatomyositis; N/A = not applicable; SCLE = subacute cutaneous lupus erythematosus; TLE = tumid lupus
erythematosus.
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ml), a concentration which gives a negative test result.
We also determined the correlation of TNFa release
with disease activity in these nine DLE patients using
the CLASI score to measure disease activity. A positive
correlation (r = 0.61, P = 0.08) was seen in DLE patients
between their disease activity and TNFa protein secre-
tion (Figure 2). There was no correlation seen in SCLE
(r = -0.05) or DM (r = 0.3493) patients between their
disease activity and TNFa protein secretion.
Myeloid dendritic cells expressing intracellular TNFa were
significantly greater in DLE and DM patients than in
controls
The dot plots shown in Figure 3 demonstrate popula-
tions of both mDCs (Figure 3A) and monocytes (Figure
3B) from representative individuals, one from each
group, who were defined and/or gated by antibodies
(upper panel) and subsequently analyzed for their ability
to produce TNFa (lower panel).
We determined the percentage of CD64+CD14+
monocytes, CD123+ pDCs, CD11c+HLA-DRhi/low mDCs
and CD3+ T lymphocytes expressing intracellular TNFa
in five DLE, five DM patients and five controls. The
results from all patients demonstrated that major produ-
cers of TNFa were monocytes and mDCs (Figure 4).
We observed a trend toward greater amounts of intra-
cellular TNFa in monocytes from both DLE and DM
patients compared to controls (P > 0.05) (Figure 4A).
There was a statistically significant difference in TNFa
intracellular staining of mDCs when both DLE (P <
0.001) and DM (P < 0.001) patients were compared to
controls (Figure 4B).
Mean fluorescence intensity of TNFa release by mDCs
and monocytes
The mean fluorescence intensity (MFI) of TNFa release
from CD64+CD14+ monocytes and CD11c+HLA-DRhi/low
mDCs was measured among five DLE and five DM
patients, as well as five controls. There was a 3.3-fold
increase in the MFI of monocytes (P < 0.01) and a 3.6-
fold increase in the MFI of mDCs (P < 0.01) from DLE
patients compared to controls (Figure 5). There was no
significant difference between the MFIs of both mono-
cytes and mDCs from DM patients compared to controls.
CD64+CD14+ monocytes and CD11c+HLA-DRhi/low myeloid
dendritic cells were not significantly greater in DLE
patients
The size of the monocyte and mDC populations was
measured in five DLE and five DM patients, as well as
Figure 1 TNFa protein production by unstimulated peripheral blood mononuclear cells from DLE, SCLE, tumid TLE and DM patients
and from controls. TLE should be written in the figure Peripheral blood mononuclear cells (PBMCs) were cultured for 24 hours, followed by
collection of supernatants. The concentration of TNFa in the supernatants was measured by ELISA. Bars show the means and SD. ***P < 0.001 vs
control PBMCs by Dunnett’s multiple comparison test. DLE = discoid lupus erythematosus, DM = dermatomyositis, TLE, tumid lupus
erythematosus, SCLE, subacute cutaneous lupus erythematosus.
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in five controls. The size of the CD64+CD14+ monocyte
population in DLE patients was 1.7-fold greater com-
pared to DM patients (P > 0.05) and 2.2-fold greater
compared to controls (P > 0.05) (Figure 6A). The size of
the CD11c+HLA-DRhi/low mDC population of DLE
patients was 1.4-fold greater compared to that of DM
patients (P > 0.05) and 3.1-fold greater than that of con-
trols (P > 0.05) (Figure 6B).
Discussion
The proinflammatory nature of TNFa in inflammatory
diseases is well-established (reviewed in [7]). TNFa
causes the upregulation of adhesion molecules and che-
mokines, which leads to attachment of inflammatory
cells to vessels, rolling, emigration and eventually che-
motaxis [24-26]. TNFa is an activating cytokine for
fibroblasts and leukocytes, including dendritic cells.
TNFa stimulation leads to increased production of IFN-
g, a cytokine that is also increased in lesional skin of
DLE patients [12]. Our study demonstrates that TNFa
release is significantly greater in PBMCs from DLE
patients compared to controls.
We next determined which specific cell type was
secreting the increased TNFa in DLE patients. Our flow
cytometry results demonstrated that the majority of
TNFa was produced by monocytes and mDCs, with a
statistically significant difference between TNFa
intracellular staining from mDCs of DLE patients (P <
0.001) and DM patients (P < 0.001) compared to con-
trols. A significantly greater MFI from monocytes and
mDCs from DLE patients compared to controls was also
present, whereas there was no statistically significant dif-
ference in MFI from monocytes and mDCs between DM
patients and controls. The significant elevation of the
MFI in DLE patients compared to controls demonstrates
that the monocytes and mDCs from DLE patients are
synthesizing TNFa in greater quantities compared to
controls. The MFI of the PBMCs from DLE patients is
significantly greater than that of controls. Our ELISA
results demonstrate an approximately 15-fold increase
in TNFa release from DLE PBMCs compared to those
seen in DM, and the flow cytometry results explain this
finding in part. We realize the monocytes and mDCs
comprise a relatively small percentage of circulating
cells and that there may be another population of cells
that we did not stain that could contribute to the
increased TNFa release in DLE. We will investigate
other cell types in the future.
We next explored whether there were any differences
between the size of the monocyte and mDC populations
among the DLE and DM patients and controls. We found
a trend toward an increased population of monocytes in
DLE patients compared to both DM patients and controls.
The mDC population was trending toward greater
Figure 2 TNFa in peripheral blood mononuclear cell supernatants from discoid lupus erythematosus (DLE) patients correlated with
Cutaneous Lupus Erythematosus Disease Area and Severity Index scores (r = 0.61).
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Figure 3 Flow cytometric analysis of intracellular TNFa production by myeloid dendritic cells and monocytes from patients and
controls. Upper panels show gating of peripheral blood mononuclear cells (PBMCs) from representative patients with discoid lupus
erythematosus (DLE), dermatomyositis (DM) or controls stained with fluorochrome-conjugated appropriate antibodies (A) myeloid dendritic cells
(lineage negative, HLADR+, CD11c+) or (B) monocytes (CD64+CD14+). Lower panels show intracellular expression of TNFa in (A) myeloid
dendritic cells or (B) monocytes. The numbers in the upper panels state the percentage of cell subset per total population of PBMCs. The
numbers in the lower panels state the percentage of myeloid dendritic cells or monocytes producing TNFa.
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numbers in DLE patients compared to controls. These
flow cytometry results support our cultured PBMC ELISA
results, which showed that there was a significantly greater
amount of TNFa released from DLE patients. The
increased amount of TNFa in monocytes and mDCs from
DLE patients and the greater size of these cell populations
in DLE patients may further explain why PBMCs from
DLE patients release greater quantities of TNFa.
Plasmacytoid DCs have been implicated in the patho-
genesis of both SLE and CLE. SLE is characterized by
elevated levels of IFNa and IFNb (both type I IFNs)
[27,28]. Because pDCs are the main cell type producing
IFNa and IFNb, they have been implicated in disease
pathogenesis. A higher proportion of pDCs are also pre-
sent in the skin than in the blood of patients with SLE
and CLE, suggesting that pDCs migrate from the circu-
lation to the skin and may play a role in the production
of skin lesions [29,30]. Our experiments demonstrate
that TNFa levels produced by PBMCs vary with the dif-
























































































Figure 4 Defining the cell population responsible for TNFa production. (A) CD64+CD14+ monocytes, (B) CD11c+HLA-DRhi/low myeloid
dendritic cells, (C) CD123+ plasmacytoid dendritic cells and (D) CD3+ T lymphocytes from five discoid lupus erythematosus (DLE) and five
dermatomyositis (DM) patients, as well as from five controls, were analyzed by flow cytometry to assess their ability to produce intracellular
TNFa. Bars show the means and SD. ***P < 0.001 vs controls by Dunnett’s multiple comparisons test.
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produced minimal amounts of TNFa compared to
monocytes and mDCs. Therefore, we postulate that
monocytes and mDCs may have a bigger role in the
pathogenesis of DLE than was originally believed. The
increased numbers of inflammatory cells seen in the
skin of DLE patients relative to DM patients and con-
trols may be explained, at least in part, by the increased
TNFa produced in DLE, given the importance of TNFa
in cell recruitment to endothelial cells and skin [25].
Flow cytometry showed that both CD11c+HLA-DRhi
and CD11c+HLA-DRlow mDCs produced TNFa and
accounted for much of the TNFa production exhibited
by PBMCs. Recently, an inflammatory mDC known as
Tip-DC (TNFa-inducible nitric oxide synthase-
producing dendritic cells) has been found in elevated
amounts in psoriasis plaques compared with nonlesional
skin from psoriasis patients and normal skin [9,31].
These Tip-DCs are CD11c+, BDCA-1- and HLA-DR+
[31]. Tip-DCs express HLA-DR at 10-fold lower levels
compared to CD11c+ and BDCA-1+ mDCs. It is possible
that some of the CD11c+HLA-DRlow mDCs in our DLE
patients might actually have been Tip-DCs. It has been
shown that bone marrow-derived monocytes accumulate
and differentiate to Tip-DCs in the spleen, liver and
lymph nodes of Trypanosoma brucei brucei-infected
mice [32]. Another type of inflammatory mDCs, known
as M-DC8+ cells, has also recently been described that







































Figure 5 Measurement of mean fluorescence intensity (MFI). The MFI of TNFa release from (A) CD64+CD14+ monocytes, (B) CD11c+HLA-
DRhi/low myeloid dendritic cells, (C) CD123+ plasmacytoid dendritic cells, and (D) CD3+ T lymphocytes from five discoid lupus erythematosus
(DLE) and five dermatomyositis (DM) patients, as well as from five controls, as determined by flow cytometry. Bars show the means and SD. **P
< 0.01 vs controls by Dunnett’s multiple comparison test.
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[33,34]. These M-DC8+ cells are able to produce signifi-
cantly greater amounts of TNFa in response to LPS
compared to M-DC8- monocytes and DCs [8,35].
Although we have not directly addressed these two
populations of mDCs in our current studies, there is a
possibility that these populations might contribute to
enhanced TNFa production in DLE patients. Further
studies designed to determine a potential role of these
predominantly tissue-based DCs are being performed.
Conclusions
Our findings suggest that DLE is associated with
increased TNFa protein production from CD64+CD14+
monocytes and CD11c+HLA-DRhi/low mDCs. The MFIs
of the monocyte and mDC populations are also
increased in DLE, suggesting that these cells likely have
a greater role in DLE than originally believed. Future
studies using surface staining for Tip-DCs and M-DC8+
mDCs by flow cytometry will allow us to explore the
role of these cell populations in DLE.
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Figure 6 Measurement of cell populations by flow cytometry. (A) CD64+CD14+ monocyte and (B) CD11c+HLA-DRhi/low myeloid dendritic
cell populations from five discoid lupus erythematosus (DLE) and five dermatomyositis (DM) patients, as well as from five controls, as
determined by flow cytometry.
Nabatian et al. Arthritis Research & Therapy 2012, 14:R1
http://arthritis-research.com/content/14/1/R1
Page 9 of 11
dendritic cell; PBMC: peripheral blood mononuclear cell; RT-PCR: real-time
polymerase chain reaction; SCLE: subacute cutaneous lupus erythematosus;
SLE: systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus
Disease Activity Index; TLE: tumid lupus erythematosus; TNFα: tumor necrosis
factor α.
Acknowledgements
This study was supported in part by a merit review grant from the
Department of Veterans Affairs, Veterans Health Administration, Office of
Research and Development, Biomedical Laboratory Research and
Development, and by National Institutes of Health (NIH) grant K24-AR 02207
(to VPW).). In addition, funding was provided by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and Development,
Biomedical Laboratory Research and Development.
Author details
1Philadelphia Veterans Affairs Medical Center, 38th and Woodland Avenues,
Philadelphia, PA 08901, USA. 2Department of Dermatology, School of
Medicine, University of Pennsylvania, 2 Maloney Building, 36th and Spruce
Streets, Philadelphia, PA 19104, USA. 3University of Medicine and Dentistry of
New Jersey-Robert Wood Johnson Medical School, 675 Hoes Lane West
Piscataway, New Brunswick, NJ 08854 USA.
Authors’ contributions
ASN and MMB carried out the PBMC cultures and TNF ELISA studies. AB and
MW participated in the flow studies, and AB drafted the manuscript. VPW
performed the CLASI assessments. VPW and ASN participated in the design
of the study. MS performed the statistical analysis. VPW conceived the study,
participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 22 November 2010 Revised: 21 September 2011
Accepted: 4 January 2012 Published: 4 January 2012
References
1. Fabbri P, Cardinali C, Giomi B, Caproni M: Cutaneous lupus erythematosus:
diagnosis and management. Am J Clin Dermatol 2003, 4:449-465.
2. Gilliam JN, Sontheimer RD: Distinctive cutaneous subsets in the spectrum
of lupus erythematosus. J Am Acad Dermatol 1981, 4:471-475.
3. Sontheimer RD: The lexicon of cutaneous lupus erythematosus: a review
and personal perspective on the nomenclature and classification of the
cutaneous manifestations of lupus erythematosus. Lupus 1997, 6:84-95.
4. Lin JH, Dutz JP, Sontheimer RD, Werth VP: Pathophysiology of cutaneous
lupus erythematosus. Clin Rev Allergy Immunol 2007, 33:85-106.
5. Caproni M, Torchia D, Cardinali C, Volpi W, Del Bianco E, D’Agata A,
Fabbri P: Infiltrating cells, related cytokines and chemokine receptors in
lesional skin of patients with dermatomyositis. Br J Dermatol 2004,
151:784-791, [see comment].
6. Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP:
Dermatomyositis: a clinicopathological study of 40 patients. Am J
Dermatopathol 2009, 31:61-67.
7. Bradley JR: TNF-mediated inflammatory disease. J Pathol 2008,
214:149-160.
8. Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von
Kietzell M, Rieber E: 6-Sulfo LacNAc, a novel carbohydrate modification of
PSGL-1, defines an inflammatory type of human dendritic cells. Immunity
2002, 17:289-301.
9. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R,
Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-
Whalen M, Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinman RM,
Krueger JG: Increase in TNF-α and inducible nitric oxide synthase-
expressing dendritic cells in psoriasis and reduction with efalizumab
(anti-CD11a). Proc Natl Acad Sci USA 2005, 102:19057-19062.
10. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF,
Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N,
Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ,
March CJ, Cerretti DP: A metalloproteinase disintegrin that releases
tumour-necrosis factor-α from cells. Nature 1997, 385:729-733.
11. Kawaguchi M, Mitsuhashi Y, Kondo S: Overexpression of tumour necrosis
factor-α-converting enzyme in psoriasis. Br J Dermatol 2005, 152:915-919.
12. Toro JR, Finlay D, Dou X, Zheng SC, LeBoit PE, Connolly MK: Detection of
type 1 cytokines in discoid lupus erythematosus. Arch Dermatol 2000,
136:1497-1501.
13. Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M,
Nyberg F: Increased expression of the novel proinflammatory cytokine
high mobility group box chromosomal protein 1 in skin lesions of
patients with lupus erthematosus. Arthr Rheum 2005, 52:3639-3645.
14. Drosera M, Facchetti F, Landolfo S, Mondini M, Nyberg F, Parodi A,
Santoro A, Zampieri S, Doria A: Role of soluble and cell surface molecules
in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol
2006, 24(1 Suppl 40):S7-S13.
15. Zampieri S, Alaibac M, Laccarino L, Rondinone R, Ghirardello A, Sarzi-
Puttini P, Doria A, Peserico A: TNF α is expressed in refractory skin lesions
from patients with subacute cutaneous lupus erythematosus. Ann Rheum
Dis 2006, 65:545-548.
16. De Bleecker JL, Meire VI, Declercq W, Van Aken EH: Immunolocalization of
tumor necrosis factor-α and its receptors in inflammatory myopathies.
Neuromuscul Disord 1999, 9:239-246.
17. Alecu M, Coman G, Alecu S: Serological levels of apoptotic bodies, sFAS
and TNF in lupus erythematosus. Rom J Intern Med 2001, 38-39:83-88.
18. Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK,
Abdel-Khalek E, El-Shafey EM, Abo-Zenah H: Proinflammatory cytokines
(TNF-α and IL-6) in Egyptian patients with SLE: its correlation with
disease activity. Cytokine 2006, 35:148-153.
19. Maczynska I, Millo B, Ratajczak-Stefańska V, Maleszka R, Szych Z, Kurpisz M,
Giedrys-Kalemba S: Proinflammatory cytokine (IL-1β, IL-6, IL-12, IL-18 and
TNF-α) levels in sera of patients with subacute cutaneous lupus
erythematosus (SCLE). Immunol Lett 2006, 102:79-82.
20. Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T: Elevation of
serum soluble tumour necrosis factor receptors in patients with
polymyositis and dermatomyositis. Clin Rheum 2000, 19:352-359.
21. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM,
Chen EH: TNFα-308A allele in juvenile dermatomyositis: association with
increased production of tumor necrosis factor α, disease duration, and
pathologic calcifications. Arthritis Rheum 2000, 43:2368-2377.
22. Krathen M, Albrecht J, Werth VP: The cutaneous lupus disease activity and
severity index as a validated outcome measure for cutaneous lupus
erythematosus: comment on the article by Stamm et al. Arthritis Rheum
2008, 59:601-602, Comment on Arthritis Rheum 2007, 57:1287-1295.
23. Yassaee M, Fiorentino D, Okawa J, Taylor L, Coley C, Troxel AB, Werth VP:
Modification of the Cutaneous Dermatomyositis Disease Area and
Severity Index, an outcome instrument. Br J Dermatol 2010, 162:669-673.
24. Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA
Jr: Two distinct monokines, interleukin 1 and tumor necrosis factor, each
independently induce biosynthesis and transient expression of the same
antigen on the surface of cultured human vascular endothelial cells. J
Immunol 1986, 136:1680-1687.
25. Munro JM, Pober JS, Cotran RS: Tumor necrosis factor and interferon-γ
induce distinct patterns of endothelial activation and associated
leukocyte accumulation in skin of Papio anubis. Am J Pathol 1989,
135:121-133.
26. Swerlick RA, Lee KH, Li KJ, Sepp NT, Caughman SW, Lawley TJ: Regulation
of vascular cell adhesion molecule 1 on human dermal microvascular
endothelial cells. J Immunol 1992, 149:698-705.
27. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of
dendritic cell differentiation by IFN-α in systemic lupus erythematosus.
Science 2001, 294:1540-1543.
28. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T: Serum levels
of interferons in patients with systemic lupus erythematosus. Clin Exp
Immunol 1987, 70:562-569.
29. Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA: Cytokine-
producing dendritic cells in the pathogenesis of inflammatory skin
diseases. J Clin Immunol 2009, 29:247-256.
30. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL:
Plasmacytoid dendritic cells (natural interferon-α/β-producing cells)
accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001,
159:237-243.
31. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I,
Pierson KC, Gonzalez J, Krueger JG, Lowes MA: Psoriasis is characterized by
Nabatian et al. Arthritis Research & Therapy 2012, 14:R1
http://arthritis-research.com/content/14/1/R1
Page 10 of 11
accumulation of immunostimulatory and Th1/Th17 cell-polarizing
myeloid dendritic cells. J Invest Dermatol 2009, 129:79-88.
32. Guilliams M, Movahedi K, Bosschaerts T, VandenDriessche T, Chuah MK,
Hérin M, Acosta-Sanchez A, Ma L, Moser M, Van Ginderachter JA, Van
Ginderachter JA, Brys L, De Baetselier P, Beschin A: IL-10 dampens TNF/
inducible nitric oxide synthase-producing dendritic cell-mediated
pathogenicity during parasitic infection. J Immunol 2009, 182:1107-1118.
33. Schäkel K, Poppe C, Mayer E, Federle C, Riethmüller G, Rieber EP: M-DC8+
leukocytes: a novel human dendritic cell population. Pathobiology 1999,
67:287-290.
34. de Baey A, Mende I, Riethmueller G, Baeuerle PA: Phenotype and function
of human dendritic cells derived from M-DC8+ monocytes. Eur J Immunol
2001, 31:1646-1655.
35. de Baey A, Mende I, Baretton G, Greiner A, Hartl WH, Baeuerle PA,
Diepolder HM: A subset of human dendritic cells in the T cell area of
mucosa-associated lymphoid tissue with a high potential to produce
TNF-α. J Immunol 2003, 170:5089-5094.
doi:10.1186/ar3549
Cite this article as: Nabatian et al.: Tumor necrosis factor a release in
peripheral blood mononuclear cells of cutaneous lupus and
dermatomyositis patients. Arthritis Research & Therapy 2012 14:R1.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Nabatian et al. Arthritis Research & Therapy 2012, 14:R1
http://arthritis-research.com/content/14/1/R1
Page 11 of 11
